Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.32 USD | -6.52% | +3.33% | +534.01% |
Apr. 11 | Sector Update: Health Care Stocks Decline Thursday Afternoon | MT |
Apr. 11 | Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 274M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-10.2
x | P/E ratio 2025 * |
-
| Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.01% |
1 day | -6.52% | ||
1 week | +3.33% | ||
Current month | +32.20% | ||
1 month | +28.02% | ||
3 months | +551.75% | ||
6 months | +932.12% | ||
Current year | +534.01% |
Managers | Title | Age | Since |
---|---|---|---|
Paul-Peter Tak
CEO | Chief Executive Officer | 64 | 20-08-31 |
Founder | 66 | 01-12-31 | |
Charles Schoch
DFI | Director of Finance/CFO | 39 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Papa
BRD | Director/Board Member | 68 | 22-08-07 |
Edward Benz
BRD | Director/Board Member | 78 | 17-08-31 |
Paul Manning
CHM | Chairman | 68 | 18-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 9.32 | -6.52% | 514,889 |
24-05-09 | 9.97 | -7.94% | 1,080,179 |
24-05-08 | 10.83 | +12.93% | 1,148,935 |
24-05-07 | 9.59 | +8.36% | 765,135 |
24-05-06 | 8.85 | -1.88% | 1,884,091 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+534.01% | 274M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- CADL Stock